A Phase 3 interventional study of CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis, sponsored by Celltrion. Completed at 20 sites in 4 countries. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-14.
Sponsored by Celltrion · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 24 in phase 3, and was the 51st registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 479 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.
Celltrion has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis
This is a double-blind, randomized, active-controlled, Phase 3 study to evaluate the efficacy, PK, PD, and safety including immunogenicity of CT-P41 compared with US-licensed Prolia in postmenopausal women with osteoporosis. All patients will also receive daily supplementation containing at least 1,000 mg of elemental calcium and at least 400 IU vitamin D from randomization to EOS visit and the data will be collected via patient's diary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
Biological: CT-P41
60 mg/mL single dose administration, Solution for injection in PFS
Biological: US-licensed Prolia
60 mg/mL single dose, Solution for injection in PFS
60 mg/mL single dose, Solution for injection in PFS
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS)
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA) and assessments of the lumbar spine (L1 to L4) were performed at a central imaging vendor. To evaluate the difference between 2 groups in the primary efficacy endpoint, the percent change from baseline in BMD for lumbar spine (L1 to L4) by DXA at Week 52 was analyzed using an analysis of covariance (ANCOVA) model coupled with multiple imputation assuming the data to be missing at random (MAR).
Time frame: baseline (screening), Week 52 predose
Percent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 52 - FAS
Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck were performed at a central imaging vendor.
Time frame: baseline (screening), Week 52 predose
Percent Change From Baseline in Lumbar Spine, Total Hip, and Femoral Neck BMD at Week 78 - FAS-TP II Subset
Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck BMD were performed at a central imaging vendor.
Time frame: baseline (screening), Week 78
Incidence of New Vertebral, Nonvertebral, and Hip Fractures During TP I - FAS
Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.
Time frame: up to Week 52 predose
Incidence of New Vertebral, Nonvertebral, and Hip Fractures During TP II - FAS-TP II Subset
Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.
Time frame: from Week 52 to Week 78
Trough Serum Concentration (Ctrough) of Denosumab at Weeks 0 and 26 - Pharmacokinetic (PK) Set
The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the lower limit of quantification (LLoQ) was set to 0 in the descriptive summaries of PK parameter estimation. In TP I, the Ctrough of denosumab at Weeks 0 and 26 was assessed as the serum concentration at Weeks 26 and 52 before the study drug administration, respectively.
Time frame: Week 0 Day 1 predose, Week 26 predose
Ctrough of Denosumab at Week 52 - PK-TP II Subset
The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation. In TP II, the Ctrough of denosumab at Week 52 was assessed as the serum concentration at Week 78.
Time frame: Week 52
Maximum Serum Concentration (Cmax) of Denosumab After First Dose - PK Set
Cmax was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation.
Time frame: from baseline (Week 0 Day 1 predose) to Week 26 predose
Percent Change From Baseline for Serum Concentration of Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) at Weeks 26 and 52 - Pharmacodynamic (PD) Set
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
Time frame: Baseline (Week 0 Day 1 predose), Weeks 26 and 52 (predose)
Percent Change From Baseline for Serum Concentration of s-CTX at Week 78 - PD-TP II Subset
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
Time frame: Baseline (Week 0 Day 1 predose), Week 78
Percent Change From Baseline for Serum Concentration of Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 26 and 52 - PD Set
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
Time frame: Baseline (Week 0 Day 1 predose), Weeks 26 and 52 (predose)
Percent Change From Baseline for Serum Concentration of P1NP at Week 78 - PD-TP II Subset
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
Time frame: Baseline (Week 0 Day 1 predose), Week 78
Number of Participants With at Least 1 Anti-drug Antibodies (ADA)/Neutralizing Antibodies (NAb) Result After the First Study Drug Administration of TP I - Safety Set
Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.
Time frame: up to Week 52 predose
Number of Participants With at Least 1 ADA/NAb Result After the First Study Drug Administration of TP II - Safety-TP II Subset
Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.
Time frame: from Week 52 to Week 78
The recruitment was conducted in 20 study centers in 4 countries.
| Milestone | CT-P41 | US-licensed Prolia | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|---|---|
| Started | 240 | 239 | 0 | 0 | 0 |
| Completed | 221 | 201 | 0 | 0 | 0 |
| Not completed | 19 | 38 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 24 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 5 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 4 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Terminated the study before the initiation of the study treatment | 1 | 1 | 0 | 0 | 0 |
| Milestone | CT-P41 | US-licensed Prolia | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 221 | 100 | 101 |
| Completed | 0 | 0 | 220 | 100 | 101 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Discontinued the study treatment before the study treatment initiation due to the adverse event | 0 | 0 | 1 | 0 | 0 |
Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA) and assessments of the lumbar spine (L1 to L4) were performed at a central imaging vendor. To evaluate the difference between 2 groups in the primary efficacy endpoint, the percent change from baseline in BMD for lumbar spine (L1 to L4) by DXA at Week 52 was analyzed using an analysis of covariance (ANCOVA) model coupled with multiple imputation assuming the data to be missing at random (MAR).
| percentage change (%) | CT-P41 | US-licensed Prolia |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 - Full Analysis Set (FAS) | 4.9597 ± 0.29977 | 5.1528 ± 0.32133 |
Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck were performed at a central imaging vendor.
| percentage change (%) | CT-P41 | US-licensed Prolia |
|---|---|---|
| Lumbar spine | 5.4913 ± 3.79907 | 5.6621 ± 3.75768 |
| Total hip | 2.7914 ± 2.87044 | 2.4253 ± 2.84061 |
| Femoral neck | 2.2295 ± 4.02031 | 1.9476 ± 3.86739 |
Bone mineral density was assessed by DXA and assessments of the lumbar spine (L1 to L4), total hip, and femoral neck BMD were performed at a central imaging vendor.
| percentage change (%) | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|
| Lumbar spine | 6.8588 ± 4.12795 | 6.5745 ± 3.40437 | 7.0532 ± 3.55985 |
| Total hip | 3.4706 ± 2.81017 | 2.7947 ± 2.79862 | 3.3837 ± 2.92786 |
| Femoral neck | 2.9995 ± 3.73072 | 2.4429 ± 3.61786 | 2.8226 ± 4.02021 |
Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.
| Participants | CT-P41 | US-licensed Prolia |
|---|---|---|
| New vertebral fracture | 1 | 1 |
| Nonvertebral fracture | 2 | 4 |
| Hip fracture | 0 | 0 |
Efficacy analysis of new vertebral fractures included only vertebral fractures occurring from T4 to L4 and confirmed by the central imaging vendor. A new vertebral fracture was defined as an increase of ≥1 grade in any vertebra from T4 to L4 that was normal at screening. The nonvertebral fractures endpoint included fractures other than those of the vertebrae, excluding the skull, facial bones, mandible, metacarpals, and phalanges (fingers or toes) since they are not associated with decreased BMD, and excluded pathologic fractures and those associated with severe trauma acquired from a fall (from a height higher than a stool, chair, or first rung of a ladder) or otherwise. Only nonvertebral fractures confirmed by the central imaging vendor were included in the efficacy analysis. The fractures occurring at the site of femur neck, femur intertrochanter, or femur subtrochanter were considered as a hip fracture.
| Participants | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|
| New vertebral fracture | 1 | 0 | 0 |
| Nonvertebral fracture | 2 | 0 | 1 |
| Hip fracture | 0 | 0 | 0 |
The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the lower limit of quantification (LLoQ) was set to 0 in the descriptive summaries of PK parameter estimation. In TP I, the Ctrough of denosumab at Weeks 0 and 26 was assessed as the serum concentration at Weeks 26 and 52 before the study drug administration, respectively.
| ng/mL | CT-P41 | US-licensed Prolia |
|---|---|---|
| Week 0 Day 1 | 46.79 ± 105.102 | 31.69 ± 73.253 |
| Week 26 | 75.64 ± 154.630 | 63.99 ± 140.912 |
The Ctrough, a concentration before the next study drug administration, was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation. In TP II, the Ctrough of denosumab at Week 52 was assessed as the serum concentration at Week 78.
| ng/mL | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|
| Ctrough of Denosumab at Week 52 - PK-TP II Subset | 70.24 ± 126.852 | 66.60 ± 129.573 | 126.15 ± 508.689 |
Cmax was calculated by non-compartmental analysis method from the concentration-time data. All serum concentrations below the LLoQ was set to 0 in the descriptive summaries of PK parameter estimation.
| ng/mL | CT-P41 | US-licensed Prolia |
|---|---|---|
| Maximum Serum Concentration (Cmax) of Denosumab After First Dose - PK Set | 5851.2 ± 32.2 | 5492.7 ± 29.8 |
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
| percentage change (%) | CT-P41 | US-licensed Prolia |
|---|---|---|
| Week 26 | -75.6972 (-83.7838 to -59.8504) | -74.3547 (-81.8667 to -63.0572) |
| Week 52 | -72.7506 (-85.8306 to -57.1429) | -72.5275 (-82.8794 to -56.6188) |
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
| percentage change (%) | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|
| Percent Change From Baseline for Serum Concentration of s-CTX at Week 78 - PD-TP II Subset | -70.4609 (-81.0680 to -46.4052) | -64.9063 (-78.9644 to -48.6034) | -70.1268 (-84.3162 to -47.4940) |
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration at each visit was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
| percentage change (%) | CT-P41 | US-licensed Prolia |
|---|---|---|
| Week 26 | -69.31 (-76.69 to -57.78) | -68.22 (-76.79 to -56.68) |
| Week 52 | -69.99 (-76.77 to -50.26) | -66.61 (-76.56 to -53.16) |
Serum concentration below the LLoQ was set to the LLoQ. The percent change from baseline for serum concentration was calculated as (\[Result at each visit - Result at Baseline\] / Result at Baseline) × 100.
| percentage change (%) | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|
| Percent Change From Baseline for Serum Concentration of P1NP at Week 78 - PD-TP II Subset | -67.05 (-76.20 to -53.24) | -68.60 (-75.12 to -50.11) | -64.54 (-78.00 to -53.92) |
Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.
| Participants | CT-P41 | US-licensed Prolia |
|---|---|---|
| ADA positive | 233 | 234 |
| NAb positive | 0 | 0 |
Samples that were positive in the ADA confirmatory assay were analyzed further to conduct a NAb assessment. The test outcomes for the screening assay were 'Positive' or 'Negative'. The number of patients with at least one ADA/NAb positive result after the first study drug administration of each treatment period including scheduled and unscheduled visits (Treatment Period I: Week 0 / Treatment Period II: Week 52) regardless of their ADA status at baseline were presented.
| Participants | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|
| ADA positive | 208 | 92 | 93 |
| NAb positive | 0 | 0 | 0 |
Collected over Through Week 78 - Treatment Period I: Adverse event start date before the study drug administration in Treatment Period II - Treatment Period II: Adverse event start date on or after the date of study drug administration in Treatment Period II.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CT-P41 | 1/239 (0.4%) | 7/239 (2.9%) | 98/239 (41%) |
| US-licensed Prolia | 0/238 (0%) | 10/238 (4.2%) | 86/238 (36.1%) |
| CT-P41 Maintenance | 1/220 (0.5%) | 8/220 (3.6%) | 44/220 (20%) |
| US-licensed Prolia Maintenance | 0/100 (0%) | 3/100 (3%) | 14/100 (14%) |
| Switched to CT-P41 | 0/101 (0%) | 0/101 (0%) | 29/101 (28.7%) |
| Event | CT-P41 | US-licensed Prolia | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|---|---|
| CataractEye disorders | 0/239 | 0/238 | 0/220 | 1/100 | 0/101 |
| Hormone level abnormalInvestigations | 0/239 | 0/238 | 0/220 | 1/100 | 0/101 |
| Benign neoplasm of adrenal glandNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/239 | 0/238 | 0/220 | 1/100 | 0/101 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/239 | 0/238 | 0/220 | 1/100 | 0/101 |
| Angina unstableCardiac disorders | 0/239 | 0/238 | 2/220 | 0/100 | 0/101 |
| Gastrointestinal perforationGastrointestinal disorders | 0/239 | 0/238 | 1/220 | 0/100 | 0/101 |
| Atrial fibrillationCardiac disorders | 0/239 | 0/238 | 1/220 | 0/100 | 0/101 |
| Acute myocardial infarctionCardiac disorders | 0/239 | 1/238 | 1/220 | 0/100 | 0/101 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/239 | 0/238 | 1/220 | 0/100 | 0/101 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/239 | 0/238 | 1/220 | 0/100 | 0/101 |
| Event | CT-P41 | US-licensed Prolia | CT-P41 Maintenance | US-licensed Prolia Maintenance | Switched to CT-P41 |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 28/239 | 26/238 | 8/220 | 3/100 | 6/101 |
| Upper respiratory tract infectionInfections and infestations | 25/239 | 20/238 | 13/220 | 4/100 | 11/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/239 | 21/238 | 7/220 | 0/100 | 1/101 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 15/239 | 5/238 | 6/220 | 3/100 | 4/101 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 9/239 | 13/238 | 2/220 | 1/100 | 2/101 |
| NasopharyngitisInfections and infestations | 10/239 | 12/238 | 4/220 | 3/100 | 4/101 |
| Urinary tract infectionInfections and infestations | 12/239 | 4/238 | 6/220 | 0/100 | 3/101 |
The overall number of participants analyzed represents the Intent-to-treat (ITT) Set. The ITT set was defined as all participants randomly assigned to receive study drug (CT-P41 or US-Prolia), regardless of whether or not any study drug was administered.
| Age, Continuous(years) | CT-P41 | US-licensed Prolia | Total |
|---|---|---|---|
| Median | 66.0 (50 to 79) | 66.0 (51 to 79) | 66.0 (50 to 79) |
| Sex: Female, Male(Participants) | CT-P41 | US-licensed Prolia | Total |
|---|---|---|---|
| Female | 240 | 239 | 479 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | CT-P41 | US-licensed Prolia | Total |
|---|---|---|---|
| Race - White | 240 | 239 | 479 |
| Ethnicity - Hispanic or Latino | 0 | 3 | 3 |
| Ethnicity - Non-Hispanic or Non-Latino | 240 | 236 | 476 |
| Body mass index(kg/m2) | CT-P41 | US-licensed Prolia | Total |
|---|---|---|---|
| Mean | 24.92 ± 4.230 | 25.23 ± 4.328 | 25.08 ± 4.277 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in May 2023, 23 months.
Results were first posted in May 2024, 11 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 23 months is close to that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab